The FDA has granted a fast review for Horizon Therapeutics’ teprotumumab for active thyroid eye disease (TED), a rare vision-threatening autoimmune condition. After accepting Horizon’s filing ...
Thyroid eye disease (TED) therapy Tepezza – the top ... and menstrual cycle changes. Tepezza (teprotumumab) became the first FDA-approved treatment for TED in 2020 and is still the only drug ...
Innovent Biologics’ Sycume receives China NMPA approval for treatment of thyroid eye disease: San Francisco Monday, March 17, 2025, 16:00 Hrs [IST] Innovent Biologics, Inc, a wo ...
Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody ...
China’s National Medical Products Administration (NMPA) approved the country’s first injectable teprotumumab biosimilar from Innovent Biologics Inc. under the brand name of Sycume (teprotumumab N-01) ...
has approved SYCUME® (teprotumumab N01, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody) for the treatment of thyroid eye disease (TED). As China's first and the world ...
New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- TEPEZZA Market Sales on the Rise Due to the Strong Growth Driven by Demand for Thyroid Eye Disease ... Amgen’s TEPEZZA (Teprotumumab-Trbw ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback